Related Experiment Videos
Troxacitabine-based therapy of refractory leukemia
1Section of Developmental Thereputics, The University of Texas M.D. Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030-4095, USA. fgiles@mdanderson.org
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
Troxacitabine, an L-nucleoside analog, shows potent anti-cancer activity and overcomes resistance to D-nucleosides. Further research is warranted for hematological malignancies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Troxacitabine is a unique L-nucleoside analog with cytotoxic properties.
- Its distinct stereochemistry confers resistance to common D-nucleoside resistance mechanisms.
Purpose of the Study:
- To evaluate the efficacy and safety of troxacitabine in patients with hematological malignancies.
- To explore its potential in overcoming drug resistance in leukemia.
Main Methods:
- Phase I and II clinical studies were conducted.
- Patients with refractory acute myeloid leukemia, chronic myeloid leukemia, and lymphoproliferative diseases were enrolled.
Main Results:
- Dose-limiting toxicities included mucositis and hand-foot syndrome.
- Observed complete and partial remissions in refractory acute myeloid leukemia patients.
- Demonstrated significant activity in blastic phase chronic myeloid leukemia.
- Combinations with ara-C, topotecan, and idarubicin showed activity in refractory AML.
Conclusions:
- Troxacitabine exhibits significant activity in hematological malignancies.
- It represents a promising therapeutic agent, particularly in drug-resistant cases.
- Further investigation in hematological malignancies is recommended.